

【Product Name】

Carcinoembryonic Antigen (eCLIA)

【Order Information】

REF NO.	Package Size
0320500501	50 T
0320500502	2×50 T
0320500503	100 T
0320500504	2×100 T

【Intended Use】

Immunoassay for in vitro quantitative determination of Carcinoembryonic Antigen (CEA) in human serum and plasma.

Carcinoembryonic Antigen (CEA), a glycoprotein, was first identified by Gold and Freedman from fetal and colon cancer tissues in 1965. It is an embryonic carcinogenic antigen with a molecular weight of about 180KDa^{1,2}.

Serum CEA is a broad - spectrum tumor marker. Clinically, it can be used for auxiliary diagnosis of colon cancer, rectal cancer, lung cancer, breast cancer, esophageal cancer, pancreatic cancer, gastric cancer, metastatic liver cancer and other common tumors. Other malignant tumors such as medullary thyroid cancer, cholangiocarcinoma, urinary malignant tumors also have varying degrees of positive rate^{3,4}. In smokers, pregnancy, colitis, colonic polyps, intestinal diverticulitis, pancreatitis, liver cirrhosis, hepatitis, benign pulmonary diseases and cardiovascular diseases, serum CEA can also be increased to varying degrees, but the percentage of positive is low^{5,6}. Serum CEA level is one of the factors to judge the prognosis of tumor, and the continuous increase of serum CEA indicates poor prognosis. The serum CEA concentration of patients with elevated CEA before treatment decreased to normal level if surgery, chemotherapy, targeted therapy or immunotherapy were effective. If the serum CEA only partially or not decreased after treatment, the treatment effect is not good^{7,8}. Serum CEA can be used for follow-up and recurrence monitoring after tumor treatment. Generally, it should be tested every 2-3 months within 2 years after treatment and every 6 months within 3 to 5 years^{9,10}.

【Principles of the testing method】

Sandwich principle. Total duration of assay: 9 minutes.

10μL of sample, biotinylated CEA monoclonal antibody and the ruthenium (Ru) complex-labeled CEA monoclonal antibody form an antigen-antibody sandwich complex, which is bound to streptavidin coated magnetic particles, and then transferred to the measuring cell where the magnetic particles are captured onto the surface of the electrode, while the unbound substances are washed away. Chemiluminescence is generated after the electrode is electrified, and the generated optical signal is measured by a photomultiplier, processed by an instrument, and the concentration of CEA in the sample is calculated based on the calibration curve.

【Main Components】

The reagent pack consists of MB, RA, RB, calibrators and control materials (optional), and different components and reagents of lot numbers should not be used interchangeably.

Components	Ingredients	Volume (2×50 T)	Volume (50 T)	Volume (100 T)	Volume (2×100 T)
(MB)	Streptavidin coated magnetic particles, 0.45 mg/mL; 0.1M phosphate-buffered saline (PBS); ProClin™300	2×1.8 mL	1×1.8 mL	1×3.5 mL	2×3.5 mL
(RB)	Biotinylated CEA antibody, 1.5 mg/L; 0.1 M PBS; ProClin™300	2×3.5 mL	1×3.5 mL	1×7.0 mL	2×7.0 mL
(RA)	Ru complex-labeled CEA antibody, 1.5 mg/L; 0.1 M PBS; ProClin™300	2×3.0 mL	1×3.0 mL	1×6.0 mL	2×6.0 mL
Calibrators	CEA antigen, 0.05 M Tris buffer, ProClin™300	High: 1×1.0 mL Low: 1×1.0mL			
Control Materials (Optional)	CEA antigen, 0.05 M Tris buffer, ProClin™300	High: 1×1.0 mL Low: 1×1.0 mL			

Traceability: This method has been standardized against the international standard substances WHO 73/601.

See the control material value sheet for the target values and ranges of control materials.

Supporting instruments and materials required but not provided in this pack (provided by Lifotronic)

Additional materials for Automated ECL Immunoassay Analyzer eCL8000, eCL8000i, eCL8000p, eCL8000x:

- [REF](#) 679005, Auffer, 480 mL, or [REF](#) 679004, Auffer, 6×480 mL
- [REF](#) 679007, Buffer, 480 mL, or [REF](#) 679006, Buffer, 6×480 mL
- [REF](#) 679009, Concentrated Washing Buffer, 1 L, or [REF](#) 679012, Assay Cup, 300 T, or [REF](#) 679011, Assay Cup, 300 T, or [REF](#) 679012, Assay Cup, 3000 T

Additional materials for Automated ECL Immunoassay Analyzer eCL8600, eCL8600i, eCL8600p, eCL8800, eCL8800i, eCL8800p:

- [REF](#) 0320501804, Auffer, 2×1 L, or [REF](#) 0320501805, Auffer, 4×1 L
- [REF](#) 0320501904, Buffer, 2×1 L, or [REF](#) 0320501905, Buffer, 4×1 L
- [REF](#) 0320507502, PreClean, 2×800 mL, or [REF](#) 0320507503, PreClean, 4×800 mL
- [REF](#) 0320510001, Assay Cup/Assay Tip, 6×6×105, or [REF](#) 032120111, Assay Cup/Assay Tip, 12×2×105

Additional materials for Automated ECL Immunoassay Analyzer eCL9000, eCL9600, eCL9900, eCL9900i:

- [REF](#) 0320501801, Auffer, 2×2 L, or [REF](#) 0320501806, Auffer, 4×2 L

- [REF](#) 0320507501, PreClean, 2×2 L, or [REF](#) 0320507504, PreClean, 4×2 L
- [REF](#) 0320510001, Assay Cup/Assay Tip, 6×6×105, or [REF](#) 0320510002, Assay Cup/Assay Tip, 1×6×105

【Storage and Shelf Life】

Store at 2°C~8°C.

Do not freeze.

Store the reagent kit upright in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagents	
Unopened store at 2°C~8°C	18 months
Store at 2°C~8°C after opening	8 weeks
Stored on the analyzers at 2°C~15°C	8 weeks

The Calibrators and Control Materials are stable up to the stated expiration date.

Stability of the Calibrators and Control Materials	
Unopened store at 2°C~8°C	18 months
Store at 2°C~8°C after opening	8 weeks

【Applicable Instrument】

Automated ECL Immunoassay Analyzers: eCL8000, eCL8000i, eCL8000p, eCL8000x, eCL8600, eCL8600i, eCL8600p, eCL8800, eCL8800i, eCL8800p, eCL9000, eCL9600, eCL9900, eCL9900i.

【Specimen collection, preparation and storage】

It is recommended to use human serum samples or plasma samples collected with EDTA-2K, EDTA-3K, heparin lithium, heparin sodium blood collection tubes.

Blood samples should be collected in accordance with the standard operation of venipuncture. After the sample is completely coagulated, centrifugation should be performed to remove residual cellular substances. The sample should be free of air bubbles during testing. Lipid layer covering the sample after centrifugation should be removed. It is not recommended to use hemolyzed samples.

Samples can be stored for 7 days at 18~28°C, 14 days at 2~8°C, and 6 months at -15°C or below. Samples should avoid repeated freeze-thaw cycles. Do not use the samples after five freeze-thaw cycles.

【Testing Procedure】
Testing procedure and precautions

Before testing, the system operation manual of the measuring instrument should be carefully read, so as to obtain relevant information such as system operating procedures, sample management, safety precautions and maintenance, and materials required for testing should be prepared. CEA testing procedures should be called and set up in accordance with the system operating procedures.

Before using the reagent, put it into the analyzer 30 minutes in advance to automatically stir the magnetic bead particles and keep them in suspension.

Recommended environment temperature for testing: 10~30°C; relative humidity: ≤ 80%.

Calibration

Calibration should be performed using lot-matching reagent and calibrators.

Before calibration, the reagent and main curve information should be imported into the analyzer via radio frequency identification reagent card (refer to instrument user manual). The analyzer adjusts the main curve to produce working curve according to the calibrator results, and identifies validity of the working curve automatically.

Recalibration is recommended when:

- (1) The reagents of different lot are used;
- (2) The same lot of reagents were used on the analyzer beyond 28 days;
- (3) Quality control findings outside the defined limits.
- (4) The Buffer of different lots are used.

Quality Control procedure

For quality control, use CEA control materials.

In addition, other suitable control material can be used.

Control materials for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Please make sure that the correct values are used.

Calculation

The system software can automatically calculate the analyte concentration, with the result in ng/mL or μg/L.

1 ng/mL CEA is equivalent to 16.9 mIU/mL.

Specimen dilution

CEA concentration in the sample higher than the upper limit of detection can be diluted with sample diluent.

The recommended dilution ratio is 1:20 (automatic dilution by instrument or manual

instrument automatic dilution, the instrument will automatically calculate the result.

【Biological Reference Interval】

By analyzing the serum samples of healthy people, it was calculated that the upper limit of the reference range of 95% is as follows.

Analysis on reference interval	All subjects	Non-smokers	Smokers
Age (years)	18-70	18-70	18-70
95 percentile	4.702	3.801	5.515
Quantity	241	121	120

Due to the differences in geography, race, gender and age, it is recommended that each laboratory determine the applicability of reference range through tests, and establish the reference range of this laboratory if necessary.

【Interpretation of results】

When interpreting the test results, it is necessary to refer to the patient's overall clinical situation, including: symptoms, medical history as well as other corresponding data and information.

【Limitations】

The test results are only for clinical reference and cannot be used alone as the basis for diagnosis or exclusion of cases.

The detection range of the kit is 0.1~1000 ng/mL. If the CEA concentration in the sample is lower than the lower limit of detection, the result is reported as < 0.1 ng/mL; if the CEA concentration in the sample is higher than the upper limit of detection, the result is reported as > 1000 ng/mL (20x diluted sample is reported as > 20000 ng/mL).

When jaundice (bilirubin) is ≤ 66 mg/dL, hemolysis (hemoglobin) is ≤ 1100 mg/dL, lipemia (triglyceride) is ≤ 1500 mg/dL, biotin is ≤ 20 ng/mL, total protein is ≤ 10 g/dL, and HAMA is ≤ 100 ng/mL in the sample, the interference deviation of the measured results is within $\pm 10.0\%$. When the concentration of rheumatoid factor in the sample is ≤ 1500 IU/mL, the relative recovery of the test results is between 90% and 110%.

When the sample contains adriamycin (100 μ g/mL), 5-fluorouracil (360 μ g/mL), methotrexate (4500 μ g/mL), cisplatin (1.5 μ g/mL) and cyclophosphamide (3000 μ g/mL), the interference deviation of the measured results is within $\pm 10.0\%$.

Samples of other tumor markers containing 1000 ng/mL AFP, 1000 U/mL CA125, 100 U/mL CA15-3, 1000 U/mL CA19-9, 100 ng/mL PSA and 1000 ng/mL Ferr are tested, and the CEA measured results are not greater than 0.2 ng/mL.

When the CEA concentration reaches 10000 ng/mL, there is no high-dose hook effect; when the CEA concentration reaches 200000 ng/mL, the test results are not be affected by the hook effect.

【Analytical Performance】

Lower limit of measurement

Limit of Blank = 0.1 ng/mL.

Limit of Detection = 0.2 ng/mL.

Accuracy

The relative deviation of its measured results is within $\pm 10.0\%$.

Linearity

Within the range of 0.2 ng/mL~1000 ng/mL, the correlation coefficient (r) of the kit should not be less than 0.9900.

Within-run imprecision (repeatability)

The coefficient of variation (CV) $\leq 5.0\%$.

Between-lot imprecision

The coefficient of variation (CV) $\leq 10.0\%$.

Homogeneity of calibrators and control materials

In-bottle homogeneity: coefficient of variation (CV) $\leq 5.0\%$.

Accuracy of calibrators

The relative deviation of its measured results is within $\pm 10.0\%$.

Measured values of quality control

The measured results of supporting assigned quality control of the kit should be within the quality control range.

Method comparison

A comparison of the Lifotronic CEA assay (y) with the Roche Elecsys CEA (x) using clinical samples gave the following correlations:

Number of plasma samples measured: 118

Linear regression:

$Y=1.105X-2.4787$

$r=0.9858$

The sample concentrations were between 0.219 and 876.8 ng/mL

【Precaution and Warning】

The kit is only used for in vitro diagnostics.

Exercise the normal precautions required for handling all laboratory reagents.

All reagents and samples including specimen, reagents, calibrators and control materials should avoid foaming before and during test.

Disposal of all waste material should be in accordance with local guidelines.

Safety data sheet available for professional user on request.

This product contains animal-sourced materials and may have potential biological risk. All samples and test wastes should be treated as the source of infection, and all wastes must be disposed according to local regulations.

Any serious incident that would be occurred in relation to the device shall be reported

in which the user and/or the patient is established.

The preservative ProClin™300 which contain Mixture of 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-Methyl-2H-isothiazol-3-one (3:1): May cause an allergic skin reaction. thus, proper personal protection should be adopt while handling the reagent: avoid breathing dust/fume/gas/mist/vapours/ spray, wear protective gloves and contaminated work clothing should not be allowed out of the workplace. If skin irritation or rash occurs: get medical advice/attention, take off contaminated clothing and wash it before reuse, and dispose of contents/container to an approved waste disposal plant.

【Symbols Explanation】

Symbol	Title of Symbol	Symbol	Title of Symbol
	Manufacturer		Consult instructions for use
	Use-by date		In vitro diagnostic medical device
	Batch code		Sufficient for <n> tests
	Serial number		Biological risks
	Temperature limit		This way up
	Authorized representative in the European Community		Indicates this device is in compliance with Europe Directive.
	Catalogue number		Material code
	Warning		Date of manufacture
	Unique device identifier		

【References】

- Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med, 1965, 121: 439-462.
- Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 1965, 122: 467-481.
- Go VLW, Zamcheck N. The role of tumor markers in the management of colorectal cancer. Cancer, 1982;50:2618-2623.
- Sell SS. Serological cancer markers. Humana Press, 1992; ISBN 0-89603-209-4.
- Fukuda I, Yamakado M, Kiyose H. Influence of Smoking on Serum Carcinoembryonic Antigen Levels in Subjects Who Underwent Multiphasic Health Testing and Services. J Med Syst 1998;22(2): 89-93.
- Ruibal Morell A. CEA serum levels in nonneoplastic disease. Int J Biol Markers 1992;7(3):160-166.
- von Kleist S, Chavanel G, Burtin P. Identification of an antigen from normal human tissue that cross-reacts with the carcinoembryonic antigen. Proc Natl Acad Sci USA, 1972;69:2492-2494.
- Matsuoka Y, Hara M, Takatsu K, Kitagawa M. Presence of antigen related to the carcinoembryonic antigen in feces of normal adults. GANN, 1973;64: 203-206.
- Duffy MJ, Van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eer J Cancer 2003;39(6):718-727.
- Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemmistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. Clin Chem, 2008;54(12):e11-e79.

【Manufacturer】

Shenzhen Lifotronic Technology Co., Ltd.

Lifotronic Tower, No. 8, Qiuzhi East Road, Guancheng Community, Guanhu Street,

Longhua, 518110 Shenzhen, PEOPLE'S REPUBLIC OF CHINA

E-mail: inter-service@lifotronic.com

【European Representative】

Shanghai International Holding Corp. GmbH (Europe)

Eiffestrasse 80, 20537 Hamburg, Germany

Tel. +49-40-2513175 Fax. +49-40-255726

【Version and Revision】

Version: 2.0

Issue Date: 2025-03-04